Analysts Jefferies initiate coverage of Freenome (FRNM) with a Buy rating and $17 target price, indicating 47% upside
Freenome is set to launch its cancer-screening services this fall, with Jefferies initiating coverage and projecting a 47% upside for the stock, indicating strong potential for growth in the cancer detection market.